Welcome to our dedicated page for NovAccess Global news (Ticker: XSNX), a resource for investors and traders seeking the latest updates and insights on NovAccess Global stock.
NovAccess Global Inc. (XSNX) is a biomedical company focused on accelerating novel cancer diagnostics and therapeutics. With a recent $10.7 million financing deal to develop immunotherapies for brain tumor patients, the company is expanding its innovative TLR-AD1 immunotherapy platform. Through groundbreaking research, including a new intellectual property license to leverage Isocitrate Dehydrogenase-1 (IDH1) as a biomarker, NovAccess Global aims to revolutionize cancer treatments by predicting patient responses to vaccine immunotherapy. The company's mission is to improve the quality of care for cancer and neurological patients worldwide.
NovAccess Global (OTCQB:XSNX), a biomedical company, has filed a provisional patent with Cedars-Sinai for a new immunotherapy platform targeting brain tumors. The patent focuses on the IDH1 protein, which aids in cellular metabolism, predicting patient responses to treatments like glioblastoma. Research led by Dr. Chris Wheeler of StemVax, a NovAccess subsidiary, reveals IDH1's role in distinguishing long-term survivors post-vaccine therapy. This filing doubles the company's patent portfolio and aims to support the development of IDH1 and TLR-AD1, an FDA-designated Orphan Drug for malignant brain tumors. NovAccess plans to meet with the FDA to co-develop these technologies, hoping to improve treatment outcomes and life expectancy for brain cancer patients.
NovAccess Global Inc. (XSNX) has postponed its Annual Meeting of Shareholders scheduled for May 2024. The company plans to reschedule the meeting soon after announcing a virtual meeting for shareholders on May 6th, 2024.
NovAccess Global Inc. (OTCQB:XSNX) has obtained a new intellectual property license from Cedars-Sinai Medical Center to enhance its immunotherapy platform for central nervous system cancer patients. The license focuses on using Isocitrate Dehydrogenase-1 (IDH1) to predict patient responses to vaccine immunotherapy for malignant brain tumors like glioblastoma. This breakthrough research by Dr. Chris Wheeler aims to improve therapeutic strategies and patient outcomes for brain cancer treatment.
FAQ
What is NovAccess Global Inc. focused on?
What recent financing deal did NovAccess Global Inc. secure?
What intellectual property license did NovAccess Global Inc. obtain?
What is NovAccess Global Inc.'s mission?
What is the goal of NovAccess Global Inc.'s TLR-AD1 platform?
